To confirm the effectiveness and safety of the DragonFly M2 Transcatheter Mitral Valve Repair System for the treatment of symptomatic moderate-to-severe (3+) or severe (4+) degenerative mitral regurgitation in high surgical risk subjects.The safety and effectiveness of the first-generation device(Dragonfly Transcatheter Mitral Valve Repair System)have been previously demonstrated. This study aims to further confirm the safety and effectiveness of the new device following structural optimization based on the first-generation design.
This is a prospective, multicentric clinical investigation. Subjects to be included in this clinical investigation suffer from symptomatic chronic moderate-to-severe (3+) or severe (4+) DMR with high or prohibitive surgical risk judged by a local investigation site's heart team . After signing an informed consent form, subjects in the experimental group will undergo the transcatheter mitral valve repair procedure using the DragonFly M2 Transcatheter Mitral Valve Clip System. All subjects were followed up immediately after procedure, before discharge, 30 days , 6 months, 12 months after procedure, and 2, 3, 4, and 5 years after procedure.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
53
Edge-to-edge repair with DragonFly M2 System
Fuwai Hospital Chinese Academy of Medical Sciences
Shenzhen, Guangdong, China
Procedure success
Procedure success: device implanted successfully, MR ≤ 2+ at discharge (or 30-day echo if unavailable), and no death or device-related reintervention within 30 days post-procedure.
Time frame: 30 Days
Single-click release success
successful clip detachment from the delivery system at the intended position during the first release attempt
Time frame: Intraoperative
Acute device success
One or more Dragonfly devices are successfully delivered and released, edge-to-edge leaflet repair confirmed by echocardiogram, and successfully withdrawal of the delivery catheter.
Time frame: Immediately after procedure
surgical intervention
surgical interventions due to post-procedural mitral valve dysfunction
Time frame: 30 days, 6 months, and 12 months
NYHA Class
Number of patients with New York Heart Association (NYHA) Function Class I or II.
Time frame: 30 days, 6 months, and 12 months
Quality of life improvement
Improvement in quality of life (QoL) over baseline, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ).
Time frame: 30 days, 6 months, and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.